<DOC>
	<DOCNO>NCT00002635</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness aminocamptothecin treat patient advance cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Aminocamptothecin Treating Patients With T-cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity aminocamptothecin ( 9-AC ) administer 72-hour infusion patient advance cutaneous T-cell lymphoma . II . Assess toxic effect 9-AC administered schedule . OUTLINE : Single-Agent Chemotherapy . Aminocamptothecin , 9-AC , NSC-603071 . PROJECTED ACCRUAL : A total 30 patient accrue ; 1 response see first 15 patient , study close . Probable duration study 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , advance stage IIB/III/IV cutaneous Tcell lymphoma Measurable evaluable disease require Measurable disease include : Skin disease evaluate clinical assessment grid method Lesion measurable imaging ( i.e. , CT measurement lymph node ) Pure osteolytic lesion Unidimensional lesion normal measurement available ( e.g. , mediastinal width xray ) Evaluable disease define malignant disease evident physical radiographic exam measurable ruler caliper , i.e . : Pelvic mass Confluent multinodular lung metastases Skin metastasis CNS metastasis eligible stable least 4 week follow completion surgery radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : ANC least 1,500 Platelets least 100,000 Hepatic : Bilirubin great 1.5 mg/dL AST le 3 time normal Renal : Creatinine great 1.5 mg/dL Other : No contraindication indwell central venous catheter No active infection include HIV No medical condition would preclude protocol compliance No pregnant nursing woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biological therapy allow Chemotherapy : Prior systemic chemotherapy allow Patients 1 prior regimen analyze separately At least 4 week since chemotherapy ( 6 week since nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : Prior skin irradiation allow At least 4 week since widefield radiotherapy Surgery : Fully recover prior surgery Other : Prior topical therapy allow Prior PUVA allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>